WallStreetZenWallStreetZen

NASDAQ: EDIT
Editas Medicine Inc Earnings & Revenue

OverviewForecastEarnings
DividendOwnership

EDIT past revenue growth

How has EDIT's revenue growth performed historically?
Company
296.32%
Industry
145.73%
Market
17.2%
EDIT's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
EDIT's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Market Performance
EDIT's revenue growth is accelerating... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

EDIT earnings and revenue history

Current Revenue
$78.1M
Current Earnings
-$153.2M
Current Profit Margin
-196.1%

EDIT Return on Equity

Current Company
-43%
Current Industry
-63.5%
Current Market
188%
EDIT's Return on Equity (-43%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when EDIT announces earnings.

EDIT Return on Assets

Current Company
-30.5%
Current Industry
2.9%
EDIT is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

EDIT Return on Capital Employed

Current Company
-39.18%
Current Industry
19.5%
EDIT's ability to generate Return... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

EDIT vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
EDIT$78.12M-$164.72M-$153.22M+19.59%N/A
CCCC$20.76M-$121.80M-$132.49M+1.40%N/A
THRD$0.00-$30.23M-$30.82MN/AN/A
TSHA$15.45M-$104.02M-$111.57M+517.55%N/A
SLRN$0.00-$381.37M-$381.64MN/AN/A
View Top Biotech Stocks

EDIT earnings dates

Next earnings date
May 3, 2024

Editas Medicine Earnings & Revenue FAQ

What were EDIT's earnings last quarter?

On Invalid Date, Editas Medicine (NASDAQ: EDIT) reported Q4 2023 earnings per share (EPS) of -$0.21, up 76.14% year over year. Total Editas Medicine earnings for the quarter were -$18.87 million. In the same quarter last year, Editas Medicine's earnings per share (EPS) was -$0.88.

If you're new to stock investing, here's how to buy Editas Medicine stock.

What was EDIT's earnings growth in the past year?

As of Q2 2024, Editas Medicine's earnings has grown year over year. Editas Medicine's earnings in the past year totalled -$153.22 million.

What is EDIT's earnings date?

Editas Medicine's earnings date is Invalid Date. Add EDIT to your watchlist to be reminded of EDIT's next earnings announcement.

What was EDIT's revenue last quarter?

On Invalid Date, Editas Medicine (NASDAQ: EDIT) reported Q4 2023 revenue of $60.05 million up 818.74% year over year. In the same quarter last year, Editas Medicine's revenue was $6.54 million.

What was EDIT's revenue growth in the past year?

As of Q2 2024, Editas Medicine's revenue has grown 296.32% year over year. This is 150.59 percentage points higher than the US Biotechnology industry revenue growth rate of 145.73%. Editas Medicine's revenue in the past year totalled $78.12 million.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.